|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
3
|
Resverlogix Corp.
|
Sep 16, 2019 04:27PM
|
|
Re: Off-label drug use in Canada and the USA
|
5
|
Resverlogix Corp.
|
Feb 05, 2021 06:51PM
|
|
Re: orphan diseases
|
2
|
Resverlogix Corp.
|
Jul 05, 2018 11:45PM
|
|
Re: orphan diseases
|
8
|
Resverlogix Corp.
|
Jul 01, 2018 03:13PM
|
|
Re: PAH Plans get a write up in Pulmonary Hypertension News
|
8
|
Resverlogix Corp.
|
May 21, 2019 01:15PM
|
|
Re: Question to ask at the AGM
|
3
|
Resverlogix Corp.
|
Oct 31, 2019 01:35PM
|
|
Re: RAAS Inhibitors in Patients with Covid-19
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 10:58AM
|
|
Re: Random thoughts RVX-208 and COVID-19
|
6
|
Resverlogix Corp.
|
Apr 12, 2020 09:47PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
3
|
Resverlogix Corp.
|
Jun 14, 2019 11:23AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 11:30AM
|
|
Re: Resverlogix AGM webcast 9/12/2018
|
9
|
Resverlogix Corp.
|
Sep 10, 2018 10:17PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 06:50PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 07:01PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:17PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:30PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
9
|
Resverlogix Corp.
|
Mar 26, 2020 01:10PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
8
|
Resverlogix Corp.
|
Mar 24, 2020 02:05PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
8
|
Resverlogix Corp.
|
Mar 26, 2020 02:36PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 24, 2020 03:54PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 24, 2020 04:20PM
|
